With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat oncology indications.